Supplementary Figure 2 from Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy

Le résumé fourni par la source

PDF file - 4938K, A. Representative patterns of tumor growth displayed in mice treated with cCD16ζ-T cells in combination with rituximab in the late phase determined using in vivo bioluminescence assay. In mice treated with cCD16ζ-T cells combined with rituximab, tumor growth at truncal sites appeared to be durably localized and suppressed. However, the brain lesion showed obvious progression, even after the second therapeutic infusion on day 24. On day 32, the cCD16ζ-T-No.8 mouse was euthanatized to examine the persistence of therapeutically infused effector cells in the spleen and BM. B. In cCD16ζ-T-No.8 mouse, all detected human cells in both the spleen and BM were CD3+ T cells, and not CD20+ Raji cells. About 20% of these residual T cells displayed cell-surface CD16, i.e., cCD16ζ-T cells defined as hCD45+CD3+CD16+. C. cCD16ζ-T cells in both the spleen (upper) and BM (lower) retained their responsiveness exclusively against rituximab-opsonized Raji cells, reflected as increased expression of CD107a.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.